Expert Interview
Discussing chronic neutropenia and the potential of Mavorixafor, a CXCR4 antagonist in development by X4 Pharmaceuticals
Ticker(s): XFORInstitution: A.R.N.A.S. Ospedale Civico Palermo
- Pediatric onco-hematologist at ARNAS Civico (Italy).
- Manages ~20 patients with neutropenia (the majority being children with autoimmune neutropenia, some SCN).
- Research focuses on autoimmune and idiopathic and autoimmune neutropenia of infants.
Roughly how many patients with chronic neutropenia do you treat?
Added By: c_adminIs there a real unmet need here?
Added By: c_adminWhat do you think of the data shown from mavorixafor so far?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
